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ABSTRACT  1 
Background. One-carbon metabolism – important for DNA stability and integrity – may play a role 2 
in breast carcinogenesis. However, epidemiological studies addressing this issue have yielded 3 
inconsistent results.  4 
Objective. We prospectively investigated associations between breast cancer and plasma folate, 5 
riboflavin, vitamin B-6, vitamin B-12, and homocysteine, in women recruited to the Varese (Italy) 6 
cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC).  7 
Methods. We performed a nested case-control study on women aged 35-65 years at recruitment, 8 
median body mass index 25.3 kg/m
2
, who gave blood samples in 1987-1992, and again in 1993-9 
1998. Breast cancer cases identified to 31 December 2009 were individually matched to controls. 10 
Relative risks (RRs) of breast cancer (and subtypes defined by hormone receptor status) with 95% 11 
confidence intervals (CIs) were estimated by unconditional logistic regression, controlling for 12 
matching factors and breast cancer risk factors.  13 
Results. After a median of 14.9 years, 276 breast cancer cases were identified and matched to 276 14 
controls. Increasing plasma vitamin B-6 was associated with decreased risk of overall (RR: 0.78; 15 
95%CI: 0.63, 0.96 for 1SD increase), premenopausal (RR: 0.66; 95%CI: 0.48, 0.92 for 1SD 16 
increase), ER+ (RR: 0.79; 95%CI: 0.63, 1.00 for 1SD increase) and PR+ (RR: 0.72; 95%CI: 0.55, 17 
0.95 for 1SD increase) breast cancers. Increasing plasma vitamin B-6 was also associated with 18 
decreased breast cancer risk in alcohol consumers (≥7 g/d) compared to consumption of <7 g/d plus 19 
non-consumption (RR: 0.71; 95% CI: 0.51, 0.99).  20 
High plasma riboflavin was associated with significantly lower risk in premenopausal women (RR: 21 
0.45; 95%CI: 0.21, 0.94 highest vs. lowest quartile, P trend=0.021). Plasma homocysteine, folate, 22 
and vitamin B-12 were not associated with breast cancer risk.  23 
Conclusions. High plasma vitamin B-6 and riboflavin may lower breast cancer risk, especially in 24 
premenopausal women. Additional research is necessary to further explore these associations.  25 
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The micronutrients folate, vitamin B-12, vitamin B-6, riboflavin, and homocysteine are all involved 31 
in one-carbon metabolism, and thus play important roles in maintaining DNA stability and integrity. 32 
Folate, as 5-methyltetrahydrofolate, is required to remethylate homocysteine to methionine which is 33 
converted to S-adenosylmethionine. The latter provides methyl groups for methylation reactions in 34 
general, and DNA and RNA biosynthesis in particular (1-5). S-adenosylmethionine depletion 35 
induces DNA hypomethylation which may lead to expression of proto-oncogenes and eventually 36 
cancer (6). Folate deficiency also results in deficient methylation of uracil to thymine, so that uracil 37 
is incorporated into DNA (2), leading to chromosome breaks and carcinogenesis (3,6). Vitamin B-38 
12 deficiency is expected to cause chromosome breaks by the same mechanism as folate since it is 39 
an essential coenzyme in the methylation of homocysteine to methionine (2,4).  40 
Vitamin B-6 is an essential coenzyme for several catabolic and anabolic reactions. In particular it is 41 
required for the conversion of tetrahydrofolate to 5,10-methylenetetrahydrofolate by serine 42 
hydroxymethyltransferase (2). 5,10-methylenetetrahydrofolate is required for the synthesis of 43 
nucleotides, themselves necessary for DNA synthesis and repair. Vitamin B-6 deficiency decreases 44 
the activity of serine hydroxymethyltransferase, thereby depleting the 5,10-45 
methylenetetrahydrofolate pool, so that uracil is incorporated into DNA and chromosome breaks 46 
occur (2). Vitamin B-6 is also necessary for the synthesis of glutathione from homocysteine: 47 
glutathione is a cofactor of glutathione-S-transferases and peroxidases, which detoxify many 48 
carcinogenic compounds and protect against oxidative DNA damage (7-9). Riboflavin is the 49 
precursor of flavin adenine dinucleotide, a necessary cofactor for 5,10-methylenetetrahydrofolate 50 
reductase (10-13), which catalyzes the irreversible conversion of 5,10-methylenetetrahydrofolate to 51 
5-methyltetrahydrofolate: the latter being the methyl donor for DNA methylation (10,11,14,15). 52 
Inadequate levels of folate, vitamin B-12, vitamin B-6, and riboflavin may all result in high levels 53 
of blood homocysteine (5,16) by disrupting the pathways summarized above (17). In vitro studies 54 
indicate that high homocysteine levels are associated with high proliferation rates of cancer cells 55 
including breast cancer cells (18,19), and also with oxidative damage to cells (20). High 56 
 5 
homocysteine levels in blood have been associated with increased breast cancer risk in women 57 
with low folate status (21), and also in women with high body mass index (BMI), high plasma 58 
triglycerides, and abnormal oxidation of low-density lipoproteins (20,22-26) – all of which are 59 
associated with increased risk of certain cancers including breast cancer (27,28). 60 
Studies on associations of plasma homocysteine (21,29-32), folate (29,30,32-34), vitamin B-12 61 
(30,32,33), and vitamin B-6 (30,32,33) with breast cancer risk, have produced mixed results. To our 62 
knowledge no previous study has assessed the effect of plasma riboflavin on breast cancer risk. We 63 
carried out a case-control study, nested in the EPIC-Varese cohort, to prospectively evaluate 64 
whether plasma levels of homocysteine, folate, vitamin B-12, vitamin B-6, and riboflavin, were 65 
associated with risk of breast cancer, and risk of breast cancer subtypes defined by expression of 66 
hormone receptors.  67 
 68 
MATERIALS AND METHODS 69 
Study population and data collection 70 
This was a case-control study nested in the women participating in the EPIC-Varese cohort study – 71 
part of the larger European Investigation into Cancer and Nutrition (EPIC). We considered 6071 72 
women defined by the following eligibility criteria: recruitment to the prospective Hormones and 73 
Diet in the Etiology of Breast Cancer (ORDET) study in 1987-1992; recruitment to EPIC-Varese in 74 
1993-1998 (70% of women who participated in ORDET were subsequently recruited in EPIC-75 
Varese); and either premenopausal or postmenopausal at the ORDET and EPIC baselines 76 
(perimenopausal women and those with uncertain menopausal status were excluded).  77 
The date of entry to the present study was the EPIC recruitment date. At EPIC baseline, after 78 
participants had given written informed consent, detailed information was collected on reproductive 79 
and medical history, physical activity, alcohol consumption, smoking, education and other 80 
socioeconomic variables using a standardized lifestyle questionnaire. Diet over the previous year 81 
was investigated using a food frequency questionnaire specifically developed to capture local 82 
dietary habits. Also at baseline, weight, height, and blood pressure were measured and a 30 mL 83 
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fasting blood sample was collected, using standardized procedures. The blood samples were 84 
divided into 0.5 mL aliquots of plasma, serum, red blood cells, and buffy coat, on the day of 85 
collection, and stored in liquid nitrogen at -196 °C (35).  86 
All study participants had also been recruited to the earlier ORDET study and at ORDET baseline 87 
had given a blood sample. The stored plasma samples were analyzed and the results of these 88 
analyses were combined with those obtained from the samples collected at the EPIC baseline, so as 89 
to obtain mean estimates that were more reliable than those provided by a single measurement. The 90 
study protocol was approved by the ethics committee of the Fondazione IRCCS Istituto Nazionale 91 
dei Tumori (Milan, Italy). 92 
Breast cancer cases and selection of control women 93 
The 6071 women were followed-up to December 31, 2009 (median 14.9 years), through the 94 
Lombardy Cancer Registry, Varese Province, characterized by high data completeness and quality. 95 
A total of 276 new breast cancer cases were identified among the women over the follow-up period 96 
from the registry database. Information on estrogen receptor (ER), progesterone receptor (PR), and 97 
human epidermal growth factor receptor (HER2) expression of the cancers was obtained from 98 
electronic pathology reports. 99 
For each case, one matched control was chosen, using an incidence density sampling protocol, from 100 
appropriate risk sets consisting of cohort members alive and free of cancer at the time of diagnosis 101 
of the index case. Matching criteria were age at recruitment (±5 years), date of recruitment (±180 102 
days), distance between ORDET and EPIC recruitment (±90 days), menopausal status 103 
(postmenopausal at both ORDET and EPIC baseline, premenopausal at ORDET baseline, 104 
postmenopausal at EPIC baseline, premenopausal at ORDET baseline and still premenopausal at 105 
EPIC baseline), and micronutrient analysis in the same batch.  106 
Analysis of plasma samples 107 
Analyses were performed both on EPIC and ORDET plasma samples. Folate and vitamin B-12 108 
were determined on a Cobas 8000 modular analyzer (Roche Diagnostic GmbH) by Roche Elecsys 109 
electrochemoluminescence assays. Homocysteine was determined immuno-enzymatically as S-110 
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adenosylhomocysteine produced from serum homocysteine on a Siemens Dimension Vista Lab 111 
System analyser (Siemens Healthcare Diagnostics Products GmbH). All assays were performed 112 
according to recommendations of the equipment manufacturers. 113 
Levels of riboflavin and vitamin B-6 (the latter as pyridoxal-5’-phosphate − PLP − principal active 114 
form of vitamin B-6) were measured by LC/MS using a Thermo Fisher LCQ Vantage mass 115 
spectrometer coupled to a Thermo Fisher Scientific Transcend HPLC system. Perchloric acid was 116 







H-labelled PLP). After incubation at 50°C for 10 118 
minutes, the treated aliquots were filtered and injected into the HPLC system and eluted with a 119 
water, methanol, ammonium acetate gradient. The mass spectrometer was operated in single 120 
reaction monitoring mode to minimize interference from other compounds. Use of internal 121 
standards made it possible to correct for losses during purification and variation in instrument 122 
response. We excluded 17 cases and 18 controls because EPIC or ORDET plasma samples were not 123 
available. 124 
Statistical analysis  125 
We calculated plasma levels of homocysteine, folate, vitamin B-12, vitamin B-6, and riboflavin for 126 
each case and control as the mean of the values from the EPIC and ORDET samples. Coefficients 127 
of variation (CV) for each, considering the ORDET and EPIC samples as replicates of a single 128 
sample were as follows: 13% for homocysteine, 16% for folate, 14% for vitamin B-12, 31% for 129 
vitamin B-6, and 23% for riboflavin. Plasma levels were grouped into quartiles based on the 130 
distribution in controls. Baseline characteristics of study participants, according to quartiles of 131 
plasma vitamin B-6, were summarized as means and standard deviations (continuous variables) or 132 
frequencies (categorical variables). Unconditional logistic regression models were used to estimate 133 
relative risks (RRs) for breast cancer with 95% confidence intervals (CIs), with lowest quartile as 134 
reference; the significance of linear trends was assessed by treating each quartile as a continuous 135 
variable in the model and performing the Wald test. RRs were also calculated for 1 standard 136 
deviation increments of micronutrient concentration as a continuous variable. We ran a minimally 137 
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adjusted model, with the matching variables − age (continuous), date of recruitment (continuous), 138 
time between ORDET and EPIC recruitment (continuous), and menopausal status 139 
(premenopausal/postmenopausal in EPIC) − as covariates. Was also ran fully-adjusted models, with 140 
the following additional covariates: family history of breast cancer in first degree relatives (yes, no), 141 
age at menarche (<15 years, ≥15 years), parity (nulliparous, 1-2 children, >2 children), oral 142 
contraceptive use (never, sometime), education (≤8 years, >8 years), smoking status (never, former, 143 
current), alcohol consumption (continuous), and BMI (continuous). 144 
We analyzed all women, and postmenopausal and premenopausal women separately. P values for 145 
interaction between plasma micronutrient with menopausal status were estimated by adding the 146 
product of quartile of plasma micronutrient with menopausal status to the model and applying the 147 
Wald test. We also analyzed risk of developing breast cancer subtypes defined by receptor status. 148 
Heterogeneity was investigated by the Wald test. We analyzed subgroups defined by alcohol intake 149 
(abstainers, <7 g/d, ≥7 g/d) with P interaction calculated by treating alcohol intake as a 150 
dichotomous variable (abstainer, consumer) and multiplying this by the analyte value (continuous). 151 
We excluded one case and two controls because confounder variables were missing; the analyses 152 
were thus performed on 514 women, 258 cases and 256 controls. All statistical tests were two-153 
sided, differences were considered significant for P <0.05. The analyses were performed with Stata 154 
version 11.2 (College Station, TX, USA). 155 
RESULTS 156 
Baseline characteristics of study participants by quartiles of plasma vitamin B-6 are shown in Table 157 
1. Women in the highest vitamin B-6 quartile tended to have lower BMI, lower plasma 158 
homocysteine, and higher levels of other B vitamins. They were also better educated, and less likely 159 
to be smokers, to have used oral contraceptives, and to have a family history of breast cancer. Table 160 
2 shows the risks (RRs) of developing breast cancer by quartiles of plasma homocysteine and B 161 
vitamins for all study women. High levels of vitamin B-6 in the continuous model were associated 162 
with decreased breast cancer risk [RR: 0.78; 95% CI: 0.63, 0.96 (fully-adjusted model)], however 163 
 9 
no reduction in risk was found in the analysis based on quartiles. None of the other micronutrients 164 
was significantly associated with risk (P trend ≥0.31). 165 
Table 3 shows risk estimates by menopausal status at baseline. Among postmenopausal women, 166 
none of the micronutrients was significantly associated with breast cancer risk (P trend ≥0.29). 167 
Among premenopausal women, high levels of vitamin B-6 were associated with significantly 168 
lowered breast cancer risk in the continuous model (RR: 0.66; 95% CI: 0.48, 0.92), however no 169 
reduction in risk was found in the analysis based on quartiles. The highest quartile of plasma 170 
riboflavin (compared to the lowest) was also associated with significantly lowered breast cancer 171 
risk [RR: 0.45; 95% CI: 0.21, 0.94, P trend 0.021 (fully adjusted model)]; there was a significant 172 
interaction between menopausal status and plasma riboflavin (P=0.021). Levels of homocysteine 173 
and the other B vitamins were not significantly associated with premenopausal breast cancer risk (P 174 
trend ≥0.22). However risk in the third quartile of vitamin B-12 concentration was significantly 175 
lower than reference (RR: 0.41; 95% CI: 0.19, 0.92). No interaction was found between menopausal 176 
status and plasma levels of homocysteine (P=0.44), folate (P=0.46), vitamin B-12 (P=0.45) or 177 
vitamin B-6 (P=0.42). 178 
Associations of plasma homocysteine and B vitamins with breast cancer subtypes defined by 179 
hormonal receptor status are shown in Supplemental Tables 1, 2, and 3. The second quartile of 180 
plasma homocysteine was associated with significantly decreased risk of ER+ disease (RR: 0.54; 181 
95% CI: 0.31, 0.96) compared to the lowest. Significant heterogeneity depending on ER status was 182 
found for plasma folate (P heterogeneity 0.045), however no significant association of folate with 183 
either ER+ (P trend=0.13) or ER- (P trend=0.24) disease was found. Significant heterogeneity 184 
depending on ER status was found for B-12 in the continuous model (P heterogeneity 0.032), again 185 
however no significant association was found with either ER+ or ER- disease. High vitamin B-6 186 
was associated with lowered risk (borderline significance) of ER+ disease in the continuous model 187 
(RR: 0.79; 95% CI: 0.63, 1.00) (Supplemental Table 1). Vitamin B-6 in the continuous model was 188 
associated with a significantly lowered risk of PR+ disease (RR: 0.72; 95% CI: 0.55, 0.95). The 189 
second quartile of plasma homocysteine was associated with a significantly lowered (by 49%) risk 190 
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of PR+ disease, and the second quartile of vitamin B-12 was associated with a significantly 191 
decreased (by 61%) risk of PR- disease compared to the first quartile. No significant heterogeneity 192 
in relation to PR status was found (P ≥0.22) (Supplemental Table 2). None of the micronutrients 193 
analyzed was associated with the risk of developing either HER2+ (P trend ≥0.07) or HER2- (P 194 
trend ≥0.30) disease, and no significant heterogeneity in relation to HER2 status was found (P 195 
≥0.09) (Supplemental Table 3).  196 
When the analyses were stratified by alcohol intake, plasma vitamin B-12 was associated with 197 
significantly increased breast cancer risk among abstainers (RR: 4.88; 95% CI: 1.16, 20.55 for the 198 
highest vs. lowest quartile), however few cases were available for this sub-analysis; P for 199 
interaction between plasma vitamin B-12 and alcohol intake was not significant. High vitamin B-6 200 
was associated with a significantly lowered breast cancer risk among women who drank >7g/d of 201 
alcohol (RR: 0.71; 95% CI: 0.51, 0.99 in the continuous model); no association was found for 202 
abstainers or women who drank ≤7g/d of alcohol. P for interaction between plasma vitamin B-6 and 203 
alcohol intake was not significant (0.87) (data not shown).  204 
 205 
DISCUSSION 206 
In this nested case-control study, considering all women, breast cancer risk decreased with 207 
increasing plasma vitamin B-6 levels. None of the other micronutrients was associated with breast 208 
cancer risk overall. However, when women were separated by menopausal status, high vitamin B-6 209 
and riboflavin were associated with significantly decreased breast cancer risk among 210 
premenopausal women. Although plasma folate and vitamin B-12 were not significantly associated 211 
with the risk of breast cancer subtype defined by ER status, there was significant heterogeneity, 212 
with a non-significantly decreased risk of ER+ disease for high folate and vitamin B-12, and non-213 
significantly increased risk of ER- disease for high folate and vitamin B-12. For increasing levels of 214 
vitamin B-6, the risks of ER+ and PR+ breast cancer decreased significantly, but heterogeneity 215 
between receptor positive and negative status was not significant. Finally, increasing vitamin B-6 216 
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was associated with decreasing breast cancer risk among women who drank >7g/day of alcohol 217 
compared to those who drank less or abstained.  218 
Previous studies on associations of plasma levels of nutrients involved in one-carbon metabolism 219 
with breast cancer risk focused mainly on homocysteine and folate. Of five studies concerned with 220 
homocysteine, two found no association (30,32), two case-control studies found that higher 221 
homocysteine levels were associated with increased breast cancer risk (29,31), and a case-control 222 
study nested in the Women’s Health Study found that homocysteine levels were not associated with 223 
overall breast cancer risk, but among women with low folate status the risk was increased if 224 
homocysteine was high (21). We found no evidence that homocysteine influenced breast cancer 225 
risk. 226 
Our finding of a null association between plasma folate and breast cancer risk is in agreement with: 227 
a nested case-control study in the Washington County serum bank (30); a case-control study 228 
conducted in Taiwan (29); and a case-control study on postmenopausal women nested in the Malmö 229 
Diet and Cancer cohort (34). Other studies found a decreased breast cancer risk for increasing blood 230 
folate levels (36,37), especially in women whose alcohol intake was high (≥15 g/d) (32). Finally, a 231 
case-control study nested in the Women’s Health Study found no association of folate with overall 232 
breast cancer risk, but that high folate was unexpectedly associated with increased risks of 233 
premenopausal, ER-positive, and PR-positive breast cancer (33).  234 
To our knowledge, only three studies have investigated plasma vitamin B-12 and breast cancer risk. 235 
One found no association (33), as did our study; another found that for high B-12 risks of overall 236 
and premenopausal breast cancer decreased (32); and the other found that risks decreased especially 237 
among women postmenopausal at recruitment (30). 238 
Our finding that high vitamin B-6 was associated with significantly lowered overall breast cancer 239 
risk is not completely in line with the results of the nested case-control study of Zhang et al. (32) 240 
which found that among postmenopausal women the association was of borderline significance, but 241 
was significant among women who drunk less that 15 g/d of alcohol. Lurie et al (38) also found that 242 
postmenopausal women with high vitamin B-6 had lowered breast cancer risk, which appeared 243 
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limited to women with ER+, PR+ and ER+PR+ cancers. Finally, two nested case-control studies 244 
found no association between plasma vitamin B-6 and overall breast cancer risk (30,33). 245 
Our finding that breast cancer risk was significantly lowered among premenopausal women with 246 
high compared to low plasma riboflavin appears unique, as we are aware of no other study to 247 
investigate riboflavin/breast cancer associations. The fact that the association was confined to 248 
premenopausal women is unexpected – but not too unexpected, given the numerous differences in 249 
terms of risk factors, prognosis and molecular biology, between breast cancer in pre- and post-250 
menopausal women; it suggests the need for further research.  251 
Vitamin B-6 and riboflavin may lower breast cancer risk through mechanisms other than one-252 
carbon metabolism, since they are essential cofactors in numerous reactions central to human 253 
metabolism (39,40). In addition, vitamin B-6 has been shown to decrease oxidative stress, cell 254 
proliferation and angiogenesis, and to enhance immune function (39,41); while low vitamin B-6 255 
concentrations have been associated with high levels of inflammatory markers (42). Certain 256 
carcinogens are metabolized by flavin-dependent enzymes, and the resulting metabolites may have 257 
either increased or decreased carcinogenicity (43). Some studies (reviewed in (44)) suggest that the 258 
risk of certain cancers is increased when riboflavin is deficient. 259 
Furthermore, both riboflavin and vitamin B-6 are cofactors in the pathway by which tryptophan is 260 
degraded to kynurenines, and many products of this pathway are neuroactive compounds with 261 
immunomodulatory effects (45). The same pathway is stimulated by inflammatory molecules and is 262 
often systematically up-regulated during an active immune response (45,46). Since inflammation 263 
has been linked to increased overall and premenopausal breast cancer risk (47,48), vitamin B-6 and 264 
riboflavin status might be linked to breast cancer risk by inflammation-related mechanisms, perhaps 265 
involving the kynurenine pathway. However few other data are available to suggest mechanisms by 266 
which low riboflavin status can increase the risk of breast cancer – an association we found in 267 
premenopausal women. 268 
Study strengths include: prospective design which rendered reverse causation unlikely as an 269 
explanation for the associations found; the availability of detailed information on lifestyle, dietary, 270 
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and anthropometric variables, which made it to possible to control for potential confounders; and 271 
the availability of two plasma samples taken approximately five years apart, which made it possible 272 
to analyze plasma micronutrient levels twice, providing estimates that are likely to be more reliable 273 
than a single measurement. A possible study limitation is that samples were collected, stored at -274 
196°C (EPIC samples) or -80°C (ORDET samples), and analyzed up to 25 years later. There may 275 
have been differential decay of the analytes over that period. However unless analyte decay varied 276 
with initial concentration (which seems unlikely) this will not bias analyte-risk associations. A 277 
stability study conducted on vitamin B-6, vitamin B-12, and folic acid in plasma with EDTA, and 278 
riboflavin in whole blood, found that no large decline had occurred after 4 years of storage at -20°C 279 
(49). Moreover, the small number of breast cancers diagnosed will have decreased the power to 280 
detect associations, especially in subgroup analyses. Another limitation is that we performed 281 
multiple statistical comparisons that were not corrected for, thereby increasing the risk of 282 
erroneously rejecting null hypotheses. Finally, little data is available on biological mechanisms that 283 
could explain associations between low vitamin B-6 and riboflavin status and increased breast 284 
cancer risk, especially among premenopausal women. 285 
To conclude, the findings of this case-control study nested in the EPIC-Varese cohort suggest that 286 
high plasma concentrations of vitamin B-6 may decrease the risk of breast cancer and particularly 287 
of ER+ breast cancer, and may also lower the risk in moderate-to-heavy drinkers (>7g/d alcohol). 288 
High plasma levels of riboflavin may decrease the risk of breast cancer in premenopausal but not 289 
postmenopausal women. Homocysteine and other the B vitamins investigated do not seem to 290 
influence breast cancer risk. Further research is required to elucidate the mechanisms by which B 291 
vitamins can influence the etiology of breast cancer. 292 
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1: 1.998-6.723 ng/mL 
(n=136) 
2: 6.724-9.438 ng/mL 
(n=132) 
3: 9.439-13.13 ng/mL 
(n=127) 
4: 13.14-109.3 ng/mL 
(n=119) 
Age, years   53.1 ± 7.4 53.7 ± 7.7 53.5 ± 8.5 53.1 ± 8.6 
Body mass index, kg/m
2 
 27.0 ± 4.7 25.6 ± 4.0 26.4 ± 5.0 25.5 ± 5.8 
Alcohol consumption, g/d  7.4 ± 10.1 9.7 ± 11.7 9.6 ± 13.5 7.5 ± 11.5 
Plasma homocysteine, mmol/L  11.5 ± 3.9 11.7 ± 4.5 11.8 ± 7.0 10.9 ± 3.0 
Plasma folate, ng/mL  6.6 ± 1.7 7.1 ± 1.9 7.7 ± 2.1 8.0 ± 2.3 
Plasma vitamin B-12, pg/mL  539.1 ± 177.7 602.8 ± 236.4 630.4 ± 337.2 605.2 ± 223.5 
Plasma riboflavin, ng/mL  7.4 ± 5.8 8.1 ± 7.2 8.0 ± 6.7 9.6 ± 12.1 
Family history of breast cancer, n (%)     
No  121 (89.0) 123 (93.2) 115 (90.5) 109 (91.6) 
Yes  15 (11.0) 9 (6.8) 12 (9.5) 10 (8.4) 
Age at menarche, n(%)     
<15 years  123 (90.4) 117 (88.6) 112 (88.2) 109 (91.6) 
≥15 years  13 (9.6) 15 (11.4) 15 (11.8) 10 (8.4) 
Menopausal status, n(%)      
Postmenopausal  69 (50.7) 75 (56.8) 72 (56.7) 62 (52.1) 
Premenopausal  67 (49.3) 57 (43.2) 55 (43.3) 57 (47.9) 
Parity, n(%)      
Nulliparous  6 (4.4) 17 (12.9) 17 (13.4) 11 (9.2) 
1-2 children  92 (67.7) 87 (65.9) 77 (60.6) 84 (70.6) 
>2 children  38 (27.9) 28 (21.2) 33 (26.0) 24 (20.2) 
Oral contraceptive use, n(%)      
Never  88 (64.7) 92 (69.7) 89 (70.1) 70 (58.8) 
Sometime  48 (35.3) 40 (30.3) 38 (29.9) 49 (41.2) 
Education, n(%)     
≤ 8 years  66 (48.5) 62 (47.0) 55 (43.3) 43 (36.1) 
>8 years  70 (51.5) 70 (53.0) 72 (56.7) 76 (63.9) 
Smoking status, n(%)      
Current smoker  29 (21.32) 20 (15.2) 17 (13.4) 14 (11.8) 
Ex-smoker  24 (17.7) 19 (14.4) 16 (12.6) 17 (14.3) 
Never smoker  83 (61.0) 93 (70.4) 94 (74.0) 88 (73.9) 
1
Values are means ± SD, or n (%).
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Table 2. RRs of developing breast cancer by quartiles of plasma homocysteine, folate, vitamin B-12, vitamin B-6, and riboflavin among 
women of the EPIC-Varese study. 
 
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 P trend Continuous (for each 1 SD increase)  
Homocysteine       
Range, mmol/L 5.971-9.541 9.542-10.44 10.45-12.21 12.22-82.70   
Cases/Controls 74/64 47/64 74/65 63/63   
RR (95%CI) 1 1 0.61 (0.37-1.02) 0.97 (0.59-1.59) 0.82 (0.49-1.38) 0.81 1.11 (0.90-1.36) 
RR (95%CI) 2 1 0.62 (0.37-1.05) 0.95 (0.58-1.56) 0.79 (0.46-1.34) 0.68 1.10 (0.89-1.36) 
Folate       
Range, ng/mL 2.609-5.968 5.969-7.218 7.219-8.599 8.600-15.35   
Cases/Controls 79/64 64/64 59/64 56/64   
RR (95%CI) 
1
 1 0.80 (0.50-1.30) 0.79 (0.48-1.28) 0.73 (0.44-1.19) 0.21 0.89 (0.75-1.06) 
RR (95%CI) 
2
 1 0.80 (0.49-1.31) 0.86 (0.52-1.44) 0.74 (0.45-1.23) 0.31 0.89 (0.75-1.07) 
Vitamin B-12       
Range, pg/mL 175.4-443.2 443.3-545.4 545.5-687.8 687.9-2310   
Cases/Controls 76/64 55/64 60/64 67/64   
RR (95%CI) 
1
 1 0.72 (0.44-1.18) 0.77 (0.47-1.26) 0.90 (0.55-1.46) 0.72 1.03 (0.86-1.22) 
RR (95%CI) 
2
 1 0.67 (0.40-1.11) 0.69 (0.42-1.15) 0.88 (0.53-1.45) 0.62 1.04 (0.86-1.25) 
Vitamin B-6       
Range, ng/mL 1.998-6.723 6.724-9.438 9.439-13.13 13.14-109.3   
Cases/Controls 72/64 68/64 63/64 55/64   
RR (95%CI) 
1
 1 0.93 (0.56-1.51) 0.86 (0.53-1.40) 0.77 (0.47-1.27) 0.29 0.80 (0.65-0.99) 
RR (95%CI) 
2
 1 0.93 (0.57-1.549 0.87 (0.52-1.43) 0.76 (0.45-1.27) 0.28 0.78 (0.63-0.96) 
Riboflavin       
Range, ng/mL 1.465-4.512 4.513-6.405 6.406-9.052 9.053-122.7   
Cases/Controls 74/64 66/64 56/65 62/63   
RR (95%CI) 
1
 1 0.92 (0.56-1.49) 0.74 (0.45-1.21) 0.87 (0.53-1.42) 0.41 1.08 (0.89-1.30) 
RR (95%CI) 
2
 1 0.88 (0.54-1.45) 0.73 (0.44-1.21) 0.83 (0.50-1.39) 0.36 1.08 (0.88-1.33) 
1 
Adjusted for age, menopausal status, recruitment date, and distance between ORDET and EPIC recruitment. 
2
 Further adjusted for family history of breast cancer, age at menarche, parity, oral contraceptive use, smoking status, education, alcohol consumption, and BMI.  
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Table 3. RRs of developing breast cancer by quartiles of plasma homocysteine, folate, vitamin B-12, vitamin B-6, and riboflavin according 
to menopausal status among women of the EPIC-Varese study. 
 
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 
P 
trend 
Continuous (for each 1 SD increase)  
Postmenopausal women       
Homocysteine       
Range, mmol/L 5.971-9.541 9.542-10.44 10.45-12.21 12.22-82.70   
Cases/Controls 27/21 24/30 44/42 43/47   
RR (95%CI) 
1
 1 0.58 (0.26-1.29) 0.80 (0.38-1.65) 0.66 (0.31-1.39) 0.47 1.04 (0.77-1.39) 
RR (95%CI) 
2
  1 0.63 (0.27-1.45) 0.77 (0.37-1.64) 0.66 (0.30-1.44) 0.43 1.05 (0.77-1.41) 
Folate       
Range, ng/mL 2.609-5.968 5.969-7.218 7.219-8.599 8.600-15.35   
Cases/Controls 37/33 32/33 35/35 34/39   
RR (95%CI) 
1
 1 0.85 (0.43-1.69) 0.93 (0.48-1.82) 0.79 (0.41-1.55) 0.58 0.95 (0.74-1.21) 
RR (95%CI) 
2
 1 0.85 (0.41-1.75) 1.15 (0.56-2.37) 0.82 (0.40-1.66) 0.77 0.95 (0.73-1.23) 
Vitamin B-12       
Range, pg/mL 175.4-443.2 443.3-545.4 545.5-687.8 687.9-2310   
Cases/Controls 42/44 29/34 34/27 33/35   
RR (95%CI) 
1
 1 0.89 (0.46-1.71) 1.27 (0.65-2.48) 1.02 (0.54-1.93) 0.44 1.11 (0.86-1.43) 
RR (95%CI) 
2
 1 0.83 (0.42-1.65) 1.13 (0.56-2.27) 0.88 (0.45-1.72) 0.91 1.04 (0.79-1.36) 
Vitamin B-6       
Range, ng/mL 1.998-6.723 6.724-9.438 9.439-13.13 13.14-109.3   
Cases/Controls 36/33 36/39 37/35 29/33   
RR (95%CI) 
1
 1 0.82 (0.43-1.60) 0.94 (0.48-1.83) 0.83 (0.42-1.67) 0.72 0.89 (0.69-1.14) 
RR (95%CI) 
2
 1 0.82 (0.41-1.64) 0.94 (0.47-1.88) 0.91 (0.43-1.89) 0.90 0.87 (0.68-1.13) 
Riboflavin       
Range, ng/mL 1.465-4.512 4.513-6.405 6.406-9.052 9.053-122.7   
Cases/Controls 34/37 36/40 33/38 35/25   
RR (95%CI) 
1
 1 1.02 (0.53-1.97) 0.95 (0.49-1.84) 1.56 (0.78-3.14) 0.29 1.33 (0.98-1.79) 
RR (95%CI) 
2
 1 0.97 (0.49-1.93) 0.92 (0.45-1.85) 1.59 (0.76-3.33) 0.29 1.36 (0.98-1.87) 
Premenopausal women       
Homocysteine       
Range, mmol/L 5.971-9.541 9.542-10.44 10.45-12.21 12.22-82.70   




 1 0.61 (0.31-1.20) 1.13 (0.56-2.26) 1.05 (0.48-2.32) 0.71 1.20 (0.84-1.71) 
RR (95%CI) 
2
 1 0.59 (0.29-1.19) 1.12 (0.55-2.28) 1.05 (0.46-2.39) 0.72 1.25 (0.85-1.83) 
Folate       
Range, ng/mL 2.609-5.968 5.969-7.218 7.219-8.599 8.600-15.35   
Cases/Controls 42/31 32/31 24/29 22/25   
RR (95%CI) 
1
 1 0.76 (0.38-1.51) 0.65 (0.31-1.33) 0.67 (0.32-1.40) 0.22 0.83 (0.64-1.08) 
RR (95%CI) 
2
 1 0.70 (0.34-1.42) 0.61 (0.28-1.30) 0.66 (0.30-1.46) 0.24 0.83 (0.63-1.09) 
Vitamin B-12       
Range, pg/mL 175.4-443.2 443.3-545.4 545.5-687.8 687.9-2310   
Cases/Controls 34/20 26/30 26/37 34/29   
RR (95%CI) 
1
 1 0.51 (0.24-1.11) 0.42 (0.20-0.89) 0.70 (0.33-1.49) 0.34 0.96 (0.75-1.22) 
RR (95%CI) 
2
 1 0.49 (0.22-1.10) 0.41 (0.19-0.92) 0.81 (0.36-1.82) 0.57 1.06 (0.81-1.39) 
Vitamin B-6       
Range, ng/mL 1.998-6.723 6.724-9.438 9.439-13.13 13.14-109.3   
Cases/Controls 36/31 32/25 26/29 26/31   
RR (95%CI) 
1
 1 1.10 (0.54-2.26) 0.77 (0.37-1.60) 0.69 (0.33-1.46) 0.24 0.70 (0.51-0.97) 
RR (95%CI) 
2
 1 1.07 (0.50-2.27) 0.80 (0.36-1.74) 0.65 (0.30-1.42) 0.22 0.66 (0.48-0.92) 
Riboflavin       
Range, ng/mL 1.465-4.512 4.513-6.405 6.406-9.052 9.053-122.7   
Cases/Controls 40/27 30/24 23/27 27/38   
RR (95%CI) 
1
 1 0.85 (0.41-1.77) 0.56 (0.26-1.18) 0.48 (0.24-0.97) 0.025 0.93 (0.74-1.17) 
RR (95%CI) 
2
 1 0.85 (0.40-1.83) 0.58 (0.27-1.26) 0.45 (0.21-0.94) 0.021 0.92 (0.73-1.17) 
1
 Adjusted for age, recruitment date, and distance between ORDET and EPIC recruitment. 
2
 Further adjusted for family history of breast cancer, age at menarche, parity, oral contraceptive use, smoking status, education, alcohol consumption, and BMI.  
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Supplemental Table 1. RRs of developing breast cancer subtypes defined by ER status according to quartiles of plasma homocysteine, 
folate, vitamin B-12, PLP vitamin B-6 and riboflavin, among women recruited to the EPIC-Varese study 
 
 ER+ ER- 









Homocysteine       
Quartile 1 (low) 59/64 1 1 8/64 1 1 
Quartile 2 33/64 0.54 (0.31-0.94) 0.54 (0.31-0.96) 12/64 1.39 (0.53-3.69) 1.43 (0.53-3.84) 
Quartile 3 56/65 0.90 (0.54-1.52) 0.90 (0.53-1.53) 10/65 1.19 (0.43-3.32) 1.12 (0.40-3.15) 
Quartile 4 (high) 50/63 0.81 (0.46-1.40) 0.79 (0.45-1.40) 11/63 1.30 (0.46-3.67) 1.21 (0.42-3.44) 
P trend  0.77 0.71  0.75 0.89 
P heterogeneity  0.63 1 /0.73 2      
Continuous  1.09 (0.85-1.41) 1.10 (0.85-1.43)  1.08 (0.69-1.69) 1.05 (0.67-1.66) 
P heterogeneity  0.95 1 /0.85 2      
Folate       
Quartile 1 (low) 65/64 1 1 6/64 1 1 
Quartile 2 49/64 0.75 (0.45-1.25) 0.72 (0.43-1.22) 11/64 1.83 (0.63-5.30) 1.95 (0.66-5.73) 
Quartile 3 43/64 0.69 (0.41-1.16) 0.73 (0.42-1.27) 14/64 2.60 (0.93-7.27) 2.92 (1.01-8.48) 
Quartile 4 (high) 41/64 0.65 (0.38-1.10) 0.65 (0.37-1.12) 10/64 1.75 (0.59-5.16) 1.83 (0.61-5.53) 
P trend  0.09 0.13  0.26 0.24 
P heterogeneity  0.043 1 /0.045 2      
Continuous  0.86 (0.71-1.04) 0.86 (0.70-1.05)  1.06 (0.77-1.47) 1.08 (0.77-1.51) 
P heterogeneity 0.22 1 /0.19 2      
Vitamin B-12       
Quartile 1 (low) 60/64 1 1 12/64 1 1 
Quartile 2 44/64 0.73 (0.43-1.24) 0.68 (0.40-1.17) 6/64 0.51 (0.18-1.45) 0.48 (0.17-1.40) 
Quartile 3 45/64 0.75 (0.44-1.27) 0.68 (0.39-1.17) 12/64 0.95 (0.39-2.31) 0.97 (0.39-2.43) 
Quartile 4 (high) 49/64 0.84 (0.50-1.41) 0.82 (0.48-1.41) 11/64 0.97 (0.39-2.38) 1.00 (0.39-2.55) 
P trend  0.52 0.45  0.81 0.74 
P heterogeneity  0.55 1 /0.46 2      
Continuous  0.92 (0.74-1.13) 0.91 (0.73-1.14)  1.26 (0.93-1.71) 1.35 (0.96-1.88) 
P heterogeneity 0.05 1 /0.032 2      
Vitamin B-6       
Quartile 1 (low) 54/64 1 1 11/64 1 1 
Quartile 2  55/64 1.01 (0.60-1.69) 1.01 (0.59-1.73) 10/64 0.88 (0.35-2.24) 0.88 (0.34-2.29) 
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Quartile 3 46/64 0.84 (0.49-1.42) 0.84 (0.48-1.45) 11/64 0.94 (0.38-2.36) 0.96 (0.37-2.49) 
Quartile 4 (high) 43/64 0.80 (0.47-1.36) 0.77 (0.44-1.34) 9/64 0.82 (0.31-2.14) 0.83 (0.30-2.28) 
P trend  0.32 0.27  0.73 0.28 
P heterogeneity  0.83 1 /0.74 2      
Continuous  0.82 (0.66-1.02) 0.79 (0.63-1.00)  0.77 (0.50-1.19) 0.74 (0.48-1.14) 
P heterogeneity 0.79 1 /0.76 2      
Riboflavin       
Quartile 1 (low) 55/64 1 1 15/64 1 1 
Quartile 2 49/64 0.91 (0.54-1.54) 0.86 (0.50-1.47) 9/64 0.63 (0.25-1.56) 0.66 (0.26-1.65) 
Quartile 3 40/65 0.72 (0.42-1.24) 0.69 (0.40-1.20) 12/65 0.76 (0.32-1.77) 0.80 (0.33-1.89) 
Quartile 4 (high) 54/63 1.02 (0.61-1.71) 0.93 (0.55-1.60) 5/63 0.34 (0.12-1.01) 0.38 (0.13-1.15) 
P trend  0.86 0.65  0.09 0.15 
P heterogeneity  0.11 1 /0.24 2      
Continuous  1.10 (0.90-1.34) 1.09 (0.88-1.36)  1.09 (0.81-1.47) 1.13 (0.83-1.54) 
P heterogeneity 0.92 1 /0.80 2      
1
 Adjusted for age, menopausal status, recruitment date, and distance between ORDET and EPIC recruitment. 
2
 Further adjusted for family history of breast cancer, age at menarche, parity, oral contraceptive use, smoking status, education, alcohol consumption, and BMI.  
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Supplemental Table 2. RRs of developing breast cancer subtypes defined by PR status according to quartiles of plasma homocysteine, 
folate, vitamin B-12, PLP vitamin B-6 and riboflavin, among women recruited to the EPIC-Varese study 
 
 PR+ PR- 









Homocysteine       
Quartile 1 (low) 49/64 1 1 19/64 1 1 
Quartile 2 25/64 0.50 (0.28-0.91) 0.51 (0.28-0.94) 21/64 1.01 (0.49-2.08) 1.02 (0.49-2.13) 
Quartile 3 45/65 0.90 (0.52-1.56) 0.90 (0.51-1.58) 19/65 0.87 (0.41-1.84) 0.83 (0.39-1.78) 
Quartile 4 (high) 39/63 0.80 (0.44-1.43) 0.80 (0.44-1.47) 20/63 0.87 (0.40-1.90) 0.80 (0.36-1.76) 
P trend  0.77 0.78  0.65 0.49 
P heterogeneity  0.83 1 /0.66 2      
Continuous  1.10 (0.85-1.44) 1.13 (0.86-1.49)  1.02 (0.71-1.46) 0.99 (0.68-1.42) 
P heterogeneity 0.66 1 /0.47 2      
Folate       
Quartile 1 (low) 52/64 1 1 19/64 1 1 
Quartile 2 38/64 0.73 (0.42-1.25) 0.70 (0.40-1.22) 22/64 1.14 (0.56-2.33) 1.15 (0.55-2.38) 
Quartile 3 37/64 0.75 (0.43-1.29) 0.80 (0.45-1.42) 19/64 1.07 (0.51-2.23) 1.14 (0.53-2.44) 
Quartile 4 (high) 31/64 0.62 (0.35-1.09) 0.60 (0.33-1.08) 19/64 1.00 (0.48-2.10) 1.04 (0.49-2.20) 
P trend  0.11 0.13  0.97 0.93 
P heterogeneity  0.26 1 /0.23 2      
Continuous  0.84 (0.68-1.03) 0.83 (0.67-1.03)  1.00 (0.78-1.29) 1.02 (0.79-1.33) 
P heterogeneity 0.21 1 /0.14 2      
Vitamin B-12       
Quartile 1 (low) 45/64 1 1 26/64 1 1 
Quartile 2 40/64 0.89 (0.51-1.54) 0.83 (0.47-1.47) 11/64 0.43 (0.19-0.95) 0.39 (0.18-0.88) 
Quartile 3 36/64 0.79 (0.45-1.40) 0.71 (0.40-1.27) 20/64 0.77 (0.39-1.55) 0.74 (0.36-1.52) 
Quartile 4 (high) 37/64 0.83 (0.47-1.46) 0.80 (0.45-1.43) 22/64 0.91 (0.46-1.79) 0.91 (0.45-1.84) 
P trend  0.47 0.37  0.97 0.97 
P heterogeneity  0.57 1 /0.48 2      
Continuous  0.93 (0.74-1.15) 0.92 (0.73-1.16)  1.09 (0.84-1.42) 1.15 (0.87-1.52) 
P heterogeneity 0.26 1 /0.16 2      
Vitamin B-6       
Quartile 1 (low) 47/64 1 1 18/64 1 1 
Quartile 2 43/64 0.91 (0.53-1.56) 0.90 (0.51-1.58) 21/64 1.12 (0.54-2.33) 1.08 (0.51-2.28) 
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Quartile 3 34/64 0.72 (0.41-1.26) 0.70 (0.39-1.26) 22/64 1.18 (0.57-2.44) 1.18 (0.56-2.46) 
Quartile 4 (high) 34/64 0.72 (0.41-1.26) 0.67 (0.37-1.21) 18/64 1.03 (0.49-2.18) 1.02 (0.47-2.24) 
P trend  0.17 0.13  0.90 0.89 
P heterogeneity  0.27 1 /0.22 2      
Continuous  0.76 (0.58-0.99) 0.72 (0.55-0.95)  0.90 (0.70-1.15) 0.86 (0.66-1.12) 
P heterogeneity 0.31 1 /0.31 2      
Riboflavin       
Quartile 1 (low) 46/64 1 1 22/64 1 1 
Quartile 2 35/64 0.78 (0.45-1.38) 0.72 (0.40-1.28) 23/64 1.07 (0.54-2.14) 1.12 (0.55-2.26) 
Quartile 3 32/65 0.70 (0.39-1.24) 0.65 (0.36-1.18) 20/65 0.85 (0.42-1.73) 0.90 (0.43-1.86) 
Quartile 4 (high) 45/63 1.01 (0.59-1.74) 0.91 (0.51-1.60) 14/63 0.66 (0.31-1.41) 0.70 (0.32-1.54) 
P trend  0.94 0.70  0.25 0.35 
P heterogeneity  0.31 1 /0.55 2      
Continuous  1.19 (0.96-1.47) 1.18 (0.94-1.48)  0.83 (0.56-1.23) 0.88 (0.59-1.30) 
P heterogeneity 0.08 1 /0.14 2      
1
 Adjusted for age, menopausal status, recruitment date, and distance between ORDET and EPIC recruitment. 
2
 Further adjusted for family history of breast cancer, age at menarche, parity, oral contraceptive use, smoking status, education, alcohol consumption, and BMI.  
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Supplemental Table 3. RRs of developing breast cancer by HER2 subtype by quartiles of plasma homocysteine, folate, vitamin B-12, 
vitamin B-6 and riboflavin among women recruited to the EPIC-Varese study. 
 
 HER2+ HER2- 









Homocysteine       
Quartile 1 (low) 15/64 1 1 46/64 1 1 
Quartile 2 7/64 0.43 (0.16-1.13) 0.44 (0.16-1.19) 32/64 0.67 (0.38-1.20) 0.67 (0.37-1.21) 
Quartile 3 7/65 0.46 (0.17-1.24) 0.40 (0.15-1.10) 46/65 0.96 (0.55-1.67) 0.94 (0.53-1.66) 
Quartile 4 (high) 7/63 0.46 (0.16-1.28) 0.40 (0.14-1.17) 42/63 0.88 (0.49-1.58) 0.86 (0.47-1.57) 
P trend  0.12 0.07  0.92 0.85 
P heterogeneity  0.15 1 /0.09 2      
Continuous  1.06 (0.66-1.71) 1.08 (0.65-1.79)  1.00 (0.75-1.33) 1.00 (0.74-1.34) 
P heterogeneity 0.80 1 /0.77 2      
Folate       
Quartile 1 (low) 10/64 1 1 47/64 1 1 
Quartile 2 5/64 0.51 (0.16-1.59) 0.51 (0.16-1.64) 46/64 0.96 (0.56-1.65) 0.91 (0.53-1.59) 
Quartile 3 10/64 1.11 (0.43-2.89) 1.30 (0.48-3.58) 38/64 0.86 (0.49-1.50) 0.91 (0.51-1.62) 
Quartile 4 (high) 11/64 1.17 (0.46-2.98) 1.26 (0.47-3.35) 35/64 0.77 (0.44-1.36) 0.77 (0.43-1.38) 
P trend  0.49 0.38  0.33 0.41 
P heterogeneity  0.23 1 /0.19 2      
Continuous  1.11 (0.80-1.55) 1.13 (0.80-1.58)  0.88 (0.72-1.08) 0.88 (0.71-1.08) 
P heterogeneity 0.18 1 /0.17 2      
Vitamin B-12       
Quartile 1 (low) 11/64 1 1 50/64 1 1 
Quartile 2 7/64 0.67 (0.24-1.84) 0.61 (0.21-1.74) 36/64 0.72 (0.41-1.26) 0.65 (0.37-1.15) 
Quartile 3 8/64 0.69 (0.25-1.84) 0.54 (0.19-1.53) 38/64 0.76 (0.43-1.32) 0.66 (0.37-1.17) 
Quartile 4 (high) 10/64 0.92 (0.36-2.35) 0.89 (0.33-2.39) 42/64 0.86 (0.50-1.48) 0.81 (0.46-1.42) 
P trend  0.87 0.74  0.63 0.45 
P heterogeneity  0.92 1 /0.94 2
      
Continuous  1.08 (0.76-1.54) 1.11 (0.75-1.65)  0.98 (0.79-1.21) 0.98 (0.78-1.22) 
P heterogeneity 0.59 1 /0.53 2      
Vitamin B-6       
Quartile 1 (low) 12/64 1 1 45/64 1 1 
Quartile 2 9/64 0.72 (0.28-1.83) 0.71 (0.27-1.88) 45/64 1.00 (0.58-1.72) 1.02 (0.58-1.79) 
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Quartile 3 9/64 0.70 (0.27-1.80) 0.67 (0.25-1.81) 39/64 0.86 (0.49-1.50) 0.88 (0.49-1.56) 
Quartile 4 (high) 6/64 0.49 (0.17-1.42) 0.43 (0.14-1.30) 37/64 0.84 (0.48-1.47) 0.84 (0.47-1.50) 
P trend  0.20 0.14  0.45 0.47 
P heterogeneity  0.40 1 /0.29 2      
Continuous  0.77 (0.48-1.23) 0.68 (0.41-1.11)  0.81 (0.64-1.03) 0.81 (0.63-1.02) 
P heterogeneity 0.81 1 /0.51 2      
Riboflavin       
Quartile 1 (low) 10/64 1 1 48/64 1 1 
Quartile 2 9/64 0.94 (0.35-2.49) 0.88 (0.32-2.40) 44/64 0.95 (0.55-1.63) 0.90 (0.51-1.57) 
Quartile 3 10/65 0.97 (0.38-2.53) 0.98 (0.36-2.63) 32/65 0.66 (0.37-1.17) 0.62 (0.34-1.12) 
Quartile 4 (high) 7/63 0.72 (0.26-2.02) 0.76 (0.26-2.23) 42/63 0.91 (0.52-1.56) 0.82 (0.46-1.44) 
P trend  0.59 0.71  0.47 0.30 
P heterogeneity  0.90 1 /0.85 2      
Continuous  0.95 (0.61-1.49) 0.99 (0.67-1.48)  1.14 (0.93-1.40) 1.13 (0.91-1.41) 
P heterogeneity 0.42 1 /0.50 2      
1 
Adjusted for age, menopausal status, recruitment date, and distance between ORDET and EPIC recruitment. 
2 
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